Related references
Note: Only part of the references are listed.Sorafenib for Patients with Hepatocellular Carcinoma and Child-Pugh B Liver Cirrhosis: Lessons Learned from a Terminated Study
Tim A. Labeur et al.
ONCOLOGIST (2020)
Pravastatin combination with sorafenib does not improve survival in advanced hepatocellular carcinoma
Jean-Louis Jouve et al.
JOURNAL OF HEPATOLOGY (2019)
Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial
Andrew X. Zhu et al.
LANCET ONCOLOGY (2019)
AASLD guidelines for the treatment of hepatocellular carcinoma
Julie K. Heimbach et al.
HEPATOLOGY (2018)
Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases
Jorge A. Marrero et al.
HEPATOLOGY (2018)
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Peter R. Galle et al.
JOURNAL OF HEPATOLOGY (2018)
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
Masatoshi Kudo et al.
LANCET (2018)
Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
G. K. Abou-Alfa et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Albumin-Bilirubin grade predicts prognosis of HCC patients with sorafenib use
Yuan-Hung Kuo et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2017)
Global trends and predictions in hepatocellular carcinoma mortality
Paola Bertuccio et al.
JOURNAL OF HEPATOLOGY (2017)
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
Jordi Bruix et al.
LANCET (2017)
Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: The GIDEON study
Jorge A. Marrero et al.
JOURNAL OF HEPATOLOGY (2016)
Systematic review with network meta-analysis: statins and risk of hepatocellular carcinoma
Yao-Yao Zhou et al.
ONCOTARGET (2016)
Liver function assessment according to the Albumin-Bilirubin (ALBI) grade in sorafenib-treated patients with advanced hepatocellular carcinoma
Sadahisa Ogasawara et al.
INVESTIGATIONAL NEW DRUGS (2015)
Assessment of Liver Function in Patients With Hepatocellular Carcinoma: A New Evidence-Based Approach-The ALBI Grade
Philip J. Johnson et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
et al.
JOURNAL OF HEPATOLOGY (2015)
Sorafenib in patients with Child-Pugh class A and B advanced hepatocellular carcinoma: a prospective feasibility analysis
T. Pressiani et al.
ANNALS OF ONCOLOGY (2013)
Safety and efficacy of sorafenib in hepatocellular carcinoma: the impact of the Child-Pugh score
A. Hollebecque et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2011)
Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma
Riccardo Lencioni et al.
SEMINARS IN LIVER DISEASE (2010)
Design and endpoints of clinical trials in hepatocellular carcinoma
Josep M. Llovet et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2008)
Sorafenib in advanced hepatocellular carcinoma
Josep M. Llovet et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Assessment of prognosis of cirrhosis
Francois Durand et al.
SEMINARS IN LIVER DISEASE (2008)
Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial
S Kawata et al.
BRITISH JOURNAL OF CANCER (2001)
Share Paper
